Drug intelligence / Profile preview

ENX-205

Development stage: Phase 1
Lead developer: Engrail Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ENX-205 is a small molecule precision neuroscience candidate being developed by Engrail Therapeutics for the treatment of posttraumatic stress disorder (PTSD) and various mood disorders. It features a unique pharmacological profile, acting as an agonist at the serotonin 5-HT1A and 5-HT2A receptors while simultaneously serving as an antagonist at the dopamine D2 and D3 receptors. This multi-receptor targeting strategy is intended to address the complex underlying neurobiology of PTSD. ENX-205 is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, pharmacokinetics, and receptor occupancy via positron emission tomography (PET) imaging in healthy volunteers.

Targets

DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on ENX-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENX-205.